Corporate Development Intern
This job is no longer available
There are still lots of open positions. Let's find the one that's right for you.
About The Position
At Clasp Therapeutics, we are revitalizing immuno-oncology's promise with next-generation T cell engagers (TCEs). Our novel TCE therapeutics enable a patient's T cells to identify and specifically destroy tumor cells with absolute precision. Our medicines' high level of precision and specificity essentially eliminate the likelihood of on-target off-tumor toxicities that have occurred with other TCEs. We have targeted our molecules to hard-to-treat tumors bearing common cancer driver mutations. Our specific platform structure targets mutated protein fragments, or peptides, that are displayed by specialized HLA and are designed to draw T cells into close contact with tumor cells. The resulting immune synapse is highly similar to a natural HLA molecule-T cell receptor interface with a high level of sensitivity, triggering T cells to destroy tumor cells. This approach enables a highly genetically selective paradigm where every patient has the opportunity to respond to treatment. Founded in 2020, we are focused on bringing the outstanding science from our world-class founders to patients. In 2023, Clasp closed a $150 million Series A financing round led by Catalio Capital Management, Third Rock Ventures, and Novo Holdings. Clasp has created a vibrant culture with people who are committed to our mission in both our Cambridge, MA, and Rockville, MD sites.
